Talar S. Habeshian

Talar S. Habeshian

Auto-generated profile, based on publicly available information

Talar S. Habeshian

Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
LLLihua Liu
Lihua Liu
THTalar S Habeshian
Talar S Habeshian
JZJuanjuan Zhang
Juanjuan Zhang
NPNoah C Peeri
Noah C Peeri
MDMengmeng Du
Mengmeng Du
VSVeronica Wendy Setiawan
Veronica Wendy Setiawan
Endometrial cancer (EC) incidence is on the rise. Although early-onset endometrial cancer (EOEC; age at diagnosis <50 years) is relatively uncommon, the incidence of EOEC has been reportedly increasing in recent decades. However, the rising EOEC has not been thoroughly described with regard to the racial and ethnic disparities and compared with late-onset EC (age at diagnosis ≥50 years). We used the Cancer in North America (CiNA) Analytic File, 1995-2018, from the North American Association of Central Cancer Registries, which allowed us to examine trends in invasive EC incidence by racial and ethnic groups and by age at diagnosis. We found striking differences for demographic and tumor characteristics as well as racial and ethnic patterns and time trends in EC incidence between EOEC and late-onset EC. The faster increases in EOEC incidence rates, especially among non-White women, mirror similar observations in other cancers, pointing to a possible link with rising obesity epidemic in younger generations.

26 March 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
THTalar S. Habeshian
Talar S. Habeshian
NPNoah C. Peeri
Noah C. Peeri
Immaculata De VivoImmaculata De Vivo
Immaculata De Vivo
Leo SchoutenLeo Schouten
Leo Schouten
XSXiao-Ou Shu
Xiao-Ou Shu
VSVeronica Wendy Setiawan
Veronica Wendy Setiawan
Background: The incidence rates of endometrial cancer are increasing, which may partly be explained by the rising prevalence of obesity, an established risk factor for endometrial cancer. Hypertension, another component of metabolic syndrome, is also increasing in prevalence, and emerging evidence suggests that it may be associated with the development of certain cancers. The role of hypertension independent of other components of metabolic syndrome in the etiology of endometrial cancer remains unclear. In this study, we evaluated hypertension as an independent risk factor for endometrial cancer and whether this association is modified by other established risk factors. Methods: We included 15,631 endometrial cancer cases and 42,239 controls matched on age, race, and study-specific factors from 29 studies in the Epidemiology of Endometrial Cancer Consortium. We used multivariable unconditional logistic regression models to estimate ORs and 95% confidence intervals (CI) to evaluate the association between hypertension and endometrial cancer and whether this association differed by study design, race/ethnicity, body mass index, diabetes status, smoking status, or reproductive factors. Results: Hypertension was associated with an increased risk of endometrial cancer (OR, 1.14; 95% CI, 1.09–1.19). There was significant heterogeneity by study design (Phet < 0.01), with a stronger magnitude of association observed among case–control versus cohort studies. Stronger associations were also noted for pre-/perimenopausal women and never users of postmenopausal hormone therapy. Conclusions: Hypertension is associated with endometrial cancer risk independently from known risk factors. Future research should focus on biologic mechanisms underlying this association. Impact: This study provides evidence that hypertension may be an independent risk factor for endometrial cancer.

25 April 2025 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
THTalar S Habeshian
Talar S Habeshian
SPSong-Yi Park
Song-Yi Park
DCDavid Conti
David Conti
LWLynne R Wilkens
Lynne R Wilkens
LMLoïc Le Marchand
Loïc Le Marchand
VSVeronica Wendy Setiawan
Veronica Wendy Setiawan

25 March 2024 in Epigenetics
Verified
Journal Article
Open access
THTalar S. Habeshian
Talar S. Habeshian
KCKimberly L. Cannavale
Kimberly L. Cannavale
JSJeff M. Slezak
Jeff M. Slezak
YSYu-Hsiang Shu
Yu-Hsiang Shu
GCGary W. Chien
Gary W. Chien
CCChun R. Chao
Chun R. Chao
Prostate cancer (PCa) is the most common cancer in men in the United States [1]. Approximately 80% of PCa cases are diagnosed at the localized stage, of which many are indolent and will not benefit...

1 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EHErin E Hahn
Erin E Hahn
ACAiyu Chen
Aiyu Chen
EHEric C. Haupt
Eric C. Haupt
LLLindsay Joe Lyons
Lindsay Joe Lyons
THTalar Habeshian
Talar Habeshian
PGPatricia A. Ganz
Patricia A. Ganz
36 Background: Risk-stratified survivorship care pathways are critical for meeting needs of cancer survivors and the oncology workforce. To support a clinical trial evaluating a survivorship model that transitions low-risk survivors to a primary care physician (PCP)-led survivorship clinic within an integrated healthcare system, we captured data on real-time clinical risk stratification of low-risk patients potentially eligible between 6 and 36 months after treatment cessation. Methods: After oncology stakeholder input, we developed a screening algorithm to identify low-risk breast and colorectal cancer (CRC) survivors from the electronic medical record based on data from pathology, treatment, and utilization records. The algorithm identified patients meeting study eligibility criteria: adult stage 0-IIb breast cancer or stage I-II CRC patients diagnosed with first primary cancer, excluding those with treatments indicative of high-risk or metastatic disease, ongoing ovarian suppression or trastuzumab treatment (breast), neoadjuvant chemotherapy (breast), or enrollment in other cancer clinical trials. Next, the treating oncologist was asked to confirm or deny patient eligibility based on low-risk criteria; if denied, ineligibility reason was requested. Characteristics and proportions of low-risk patients confirmed/denied eligibility and reasons for ineligibility are summarized. Results: 530 patients were identified and evaluated: 488 breast and 42 CRC. Mean age was 61 years (SD: 11.6, range 23-95); 96% female; 22% had stage 0 disease (breast only), 51% stage I, and 28% stage II. By cancer type, 390 breast patients were deemed eligible (80%); 31 CRC patients were eligible (74%). A greater proportion of Asian and Black patients were categorized eligible vs. ineligible (13% vs. 9%, and 25% vs.14%, respectively), and a smaller proportion of Hispanic and White were categorized eligible (26% vs. 33%, and 31% vs. 42%, respectively). Reasons for ineligibility included: suspicious for recurrence (6%), new primary disease (3%), complex case/condition (36%), patient preference (34%), and other/none (22%). “Complex case/condition” included reasons such as intolerance of chemotherapy, patient declined chemotherapy and/or endocrine treatment (breast), co-occurring hematology disorder; “other/none” included reasons such as current pregnancy Lynch syndrome, and no reason. Conclusions: Oncologists confirmed eligibility for 80% of algorithm-identified low-risk patients for referral to the PCP-led survivorship clinic. Of those ineligible, patient preference and complex case/condition were the most common reasons reported for ineligibility. Consensus-based risk algorithms supported by clinician review can quickly and effectively perform case identification of low-risk patients who may be appropriately transitioned to other settings for survivorship care.

3 June 2024
Verified
Other
Open access
THTalar S. Habeshian
Talar S. Habeshian
NPNoah C. Peeri
Noah C. Peeri
Immaculata De VivoImmaculata De Vivo
Immaculata De Vivo
Leo SchoutenLeo Schouten
Leo Schouten
XSXiao-Ou Shu
Xiao-Ou Shu
VSVeronica Wendy Setiawan
Veronica Wendy Setiawan
Figure S1 shows the study flowchart for the inclusion of participants. It depicts how we arrived at our final analytic population.